Join
Live feed
·
INSIDERFilingvia Quantisnow
Soleno Therapeutics Inc. logo

Sr. VP of Clinical Development Huang Michael F. returned 39,823 shares to the company, closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
SLNO· Soleno Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLNO (Soleno Therapeutics Inc.) and more on Quantisnow.